Signaling pathway revealed through which a promising anti-leukemia drug kills cancer cells

May 14, 2015, Cold Spring Harbor Laboratory

Inhibiting a protein called BRD4 critical to the survival of acute myeloid leukemia (AML) cells has shown to be an effective therapeutic strategy. However, the mechanism that explains how the protein works has remained a mystery. Now, scientists at Cold Spring Harbor Laboratory (CSHL) have discovered the larger cancer-causing pathway that the protein fits into.

The discovery points to additional molecular targets for the development of drugs to treat AML as well as other cancers. The results appear online today in Molecular Cell.

In 2011, CSHL Associate Professor Christopher Vakoc and colleagues identified potential drug targets for AML—a relatively rare blood cell cancer—using a technology called RNA interference, in which RNA molecules are mobilized to inhibit gene expression. "We systematically went hunting for things required by to grow and thrive," says Vakoc.

Out of that approach came BRD4—a protein that affects epigenetic marks, chemical groups that attach to DNA at specific locations, influencing which genes are turned on and which are turned off. Leukemia were found to be extremely sensitive to perturbing the BRD4 protein. In a bit of serendipity, drugs to inhibit BRD4 had just been developed for other purposes. Vakoc and his colleagues tested these drugs and found that one in particular, called JQ1, worked well against a mouse model of the most aggressive form of AML. "That disease was basically untreatable until we stumbled on BRD4 and the drug that targets it," says Vakoc.

In the past few years, several groups have reported similar therapeutic results in mice using JQ1 and closely related drugs. "It's been very satisfying to see that other groups have independently validated our findings," says Vakoc.

Due to the overwhelming evidence of their effectiveness in mice, inhibitors of BRD4 moved into clinical trials starting in 2013. Currently, there are 12 active clinical trials targeting BRD4 in leukemia and other cancers, including one sponsored by a company to which Vakoc has licensed JQ1. Last year, clinical trial findings presented at a conference indicated that an oral inhibitor of BRD4 similar to JQ1 had led to complete remission in some patients.

"Once we published the first paper in 2011, the main objective in our lab has been to understand why these drugs work," says Vakoc. "Knowing the mechanism of action of a drug is essential to making the drug better because there will likely be many generations of BRD4 inhibitors."

In the current study, the researchers discovered that BRD4 works very closely with an ensemble of proteins called that also bind to DNA and very selectively control the activity of certain genes. The transcription factors that BRD4 associates with control blood formation and essentially give blood cells their identity. In leukemia, which Vakoc calls a disorder of mistaken blood identity, blood cells undergo genetic changes that prevent stem cells from maturing to . "They try to be immortal by staying forever," says Vakoc.

The result is leukemia: an accumulation of immature cells with no useful function that crowd out viable blood cells in bone marrow, thereby decreasing the ability to fight infection and form blood clots in response to injury. Anemia eventually develops because the blood cannot sufficiently supply the body with oxygen.

The team has now discovered that the drug JQ1 can make leukemia cells shed their leukemia characteristics and mature, or differentiate, into normal white blood cells.

The team also identified an intermediary molecule called p300 between BRD4 and the leukemia-associated transcription factors. Active areas of research in Vakoc's lab include exploring other players in the pathway, particularly the molecules that BRD4 controls, and learning more about the transcription factors. "This new work is leading us to realize that transcription factors are the masters of the biological universe," Vakoc says. "Clearly they are driving the cancer phenotype."

In a related study from the Vakoc lab that was published April 25 in eLife, the team identified a way to target a protein called TRIM33 as a means of modulating the actions of a transcription factor called PU.1 in B-cell lymphoblastic leukemia, a cancer of that make antibodies. Although parallels exist between the activity of BRD4 and TRIM33, a major difference lies in the specificity of the proteins. TRIM33 is associated with a single transcription factor at a single binding site on the gene. In contrast, BRD4 is associated with many transcription factors at many binding sites throughout the gene.

"Our work raises a really provocative question," says Vakoc. "What if we target transcription factors directly? Would our therapies be more effective if we went to the source?"

Directly targeting transcription factors could be much more effective than chemotherapy, he speculates. Chemotherapy makes all growing cells sick—cancer cells, but also cells in the gut, skin, and blood, among others. "There's no specificity as to which tissues are affected," says Vakoc. "Transcription factor targeting, on the other hand, would really zero in on one type of tissue."

Explore further: Using CRISPR, biologists find a way to comprehensively identify anti-cancer drug targets

More information: "BET bromodomain inhibition suppresses the functional output of hematopoietic transcription factors in acute myeloid leukemia," appears online May 14, 2015 in Molecular Cell. The authors are Jae-Seok Roe, Fatih Mercan, Keith Rivera, Darryl J. Pappin, and Christopher R. Vakoc. The paper can be viewed at:

Related Stories

Using CRISPR, biologists find a way to comprehensively identify anti-cancer drug targets

May 11, 2015
Imagine having a complete catalog of the best drug targets to hit in a particularly deadly form of cancer. Imagine having a master catalog of such targets for all the major cancer types and subtypes. Scientists at Cold Spring ...

Researchers test treatment that can halt acute myeloid leukemia

April 24, 2015
Acute myeloid leukemia is a conundrum among cancers. Immature cells swamp the bone marrow, crowd out healthy cells, and all too often can have devastating consequences.

Scientists discover how leukemia cells exploit 'enhancer' DNA elements to cause lethal disease

November 26, 2013
A team of researchers at Cold Spring Harbor Laboratory (CSHL) has identified a leukemia-specific stretch of DNA called an enhancer element that enables cancerous blood cells to proliferate in Acute Myeloid Leukemia (AML), ...

Researchers identify new strategy for interfering with potent cancer-causing gene

February 11, 2013
Acute myeloid leukemia (AML) is an aggressive blood cancer that is currently incurable in 70% of patients. In a bold effort, CSHL scientists are among those identifying and characterizing the molecular mechanisms responsible ...

'Druggable' protein complex identified as a therapeutic target in acute myeloid leukemia

April 2, 2012
Scientists at Cold Spring Harbor Laboratory have identified a candidate drug target for treating acute myeloid leukemia (AML), a white blood cell cancer that proliferates out of control in the bone marrow. The team, led by ...

Unconventional hunt for new cancer targets leads to a powerful drug candidate for leukemia

August 3, 2011
Scientists at Cold Spring Harbor Laboratory (CSHL) and five other institutions have used an unconventional approach to cancer drug discovery to identify a new potential treatment for acute myeloid leukemia (AML). As reported ...

Recommended for you

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

New insight into stem cell behaviour highlights therapeutic target for cancer treatment

December 12, 2018
Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration – a protein called Prominin-1.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.